Chinese companies are conducting clinical trials of vaccines in many countries and China is actively participating in international cooperation on vaccines, Chinese Foreign Ministry spokesperson Zhao Lijian said at a press conference.
Vaccine is a powerful weapon against coronavirus. Since the outbreak of COVID-19, China adopted five technological approaches to develop COVID-19 vaccines, including inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza viruses as vectors, Zhao said.
Chinese vaccine companies and researchers are sparing no effort to advance their vaccine research and development, and several of them have entered phase three clinical trials in the United Arab Emirates, Brazil, Pakistan, Peru and other countries. China is also speeding up the phase one and phase two clinical trials of several other vaccines, Zhao stressed.
Zhao noted that the Chinese government and enterprises have been actively participating in international cooperation on vaccines through bilateral and multilateral channels. China has maintained close communication and cooperation with the World Health Organization, the Global Alliance for Vaccines and Immunization, the Coalition for Epidemic Preparedness Innovations and other international organizations. China has also joined the WHO initiative to work for global equitable access to new tools for COVID-19 prevention and control, and the Solidarity Trial for COVID-19 treatment.
"We hope that when our vaccine research and development is completed, it will be included in the procurement list of the implementation plan at an early date to make China's contribution to the accessibility and affordability of vaccines in developing countries," Zhao said.
(Compiled by Liu Kechen)